Bill Miller's Q4 Additions Struggle Amid Market Uncertainty, What Else Is Dragging Them Down?
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 25 2025
0mins
Source: Benzinga
Investment Losses: Bill Miller IV's investment firm, Miller Value Partners, has reported significant losses in its fourth-quarter portfolio additions due to market uncertainties, with all three newly added stocks experiencing substantial declines.
Potential Upside: Despite the losses, analysts suggest potential recoveries for the affected stocks, with projected gains for Carlyle Group, Atkore, and Semler Scientific, reflecting a contrarian value investing philosophy inspired by Bill Miller III.
Analyst Views on SMLR
Wall Street analysts forecast SMLR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SMLR is 51.00 USD with a low forecast of 51.00 USD and a high forecast of 51.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 20.330
Low
51.00
Averages
51.00
High
51.00
Current: 20.330
Low
51.00
Averages
51.00
High
51.00
About SMLR
Semler Scientific, Inc. is engaged in developing and marketing technology products and services to healthcare providers to combat chronic diseases. The Company's flagship product, QuantaFlo, which is patented and cleared by the United States Food and Drug Administration (FDA), is a rapid point-of-care test that measures arterial blood flow in the extremities. The QuantaFlo test aids in the diagnosis of cardiovascular diseases, such as peripheral arterial disease (PAD), and the Company is seeking a new 510(k) clearance for expanded-indications. QuantaFlo is used by healthcare providers to evaluate their patient's risk of mortality and major adverse cardiovascular events (MACE). QuantaFlo features a sensor clamp that is placed on the toe or finger. A blood flow waveform is instantaneously constructed by its software algorithm. The Company delivers QuantaFlo directly to its customers. The Company also invests in bitcoin and has adopted Bitcoin as its primary treasury asset.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
